Valeritas, inc issued the following announcement on May 14.
Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with diabetes V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch and can eliminate the need for taking multiple daily shots, announced today the publication last week of a manuscript titled “Clinical Benefits Over Time Associated with Use of V-Go Wearable Insulin Delivery Device in Adult Patients with Diabetes: a Retrospective Analysis” in Advances in Therapy, an international, peer-reviewed journal. The 14-month analysis showed that patients with diabetes benefited from significant and sustained reductions in A1C compared to baseline over time with V-Go use.
“Diabetes is a chronic progressive disease and managing multiple insulin injections can be a constant challenge for patients with diabetes when a basal-bolus insulin regimen is required to reach treatment goals,” said Dr. David Sutton, lead author and Co-Founder, Northeast Florida Endocrine and Diabetes Associates, LLC in Jacksonville, Florida, US. “We are encouraged to see the clinical benefits of V-Go are sustained over time.”
The current study demonstrated V-Go use was associated with improved A1C which was sustained for over a year in 103 patients with diabetes in a real-world setting. Reductions in A1C with V-Go ranged from 1.3 – 1.7% over the course of the study. At baseline, 33% of patients used two or more concomitant medications and, by 14 months this was reduced by more than half to 15% of patients. Therefore, the improvements in A1C seen in the study were not attributable to changes in concomitant non-insulin glucose lowering medications. Further, improvements in A1C were achieved using less insulin. Patients prescribed basal-bolus regimens with conventional insulin delivery at baseline observed a reduction in insulin of nearly 30% after switching to V-Go.
“V-Go provides patients a simpler and more convenient alternative to having to take multiple daily shots in order to deliver basal-bolus insulin and we are pleased to see additional evidence published supporting the benefits of V-Go for insulin delivery in patients with diabetes.” said John Timberlake, President and Chief Executive Officer of Valeritas.
Original source can be found here.